Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8900 results

  1. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  5. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  6. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    In development Reference number: GID-TA11416 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  7. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  12 August 2026

    Technology appraisal guidance
    In development

  8. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  9. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  10. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

    In development Reference number: GID-TA11115 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  13. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  14. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  15. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    Awaiting development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    Awaiting development